Cannabinoids

Pharmaceutical INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs Manufacturing BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing Investors News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Corporate Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Learn INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Pharmaceutical INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs Manufacturing BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing Investors News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Corporate Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Learn INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Vancouver, British Columbia–(Newsfile Corp. – June 13, 2025) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company“), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that Marcum LLP has resigned as InMed’s auditor following the acquisition of Marcum’s attest business by CBIZ CPAs P.C., with an effective resignation date of June 12, 2025 (the “Marcum Acquisition“). As a result of the Marcum Acquisition, the Company has engaged and appointed CBIZ as its new auditor for the fiscal year ending June 30, 2025. Marcum’s resignation was not due to any disagreements or reportable events related to InMed’s financial statements for the fiscal year ended June 30, 2024. The audit reports for these periods did not contain adverse opinions or disclaimers and were not qualified regarding uncertainty, audit scope, or accounting principles, except for a material weakness related to the adequacy of resources available to respond to financial reporting matters other than in the normal course of business that was previously disclosed under the heading “Item 9A. Controls and Procedures” in the Company’s Annual Report on Form 10-K for the year ended June 30, 2023. InMed further announces that its special meeting of shareholders was held today and was convened without any business being conducted, due to lack of the required quorum. Consequently, the proposed resolution to approve the potential issuance of 20% or more of the Company’s issued and outstanding common shares as of December 13, 2024 pursuant to the Standby Equity Purchase Agreement (the “SEPA“) with YA II PN, Ltd. (“Yorkville“), and pursuant to Nasdaq Listing Rules 5635(d) and 5635(b) (the “Share Issuance Proposal“) was not formally voted on. The Company intends to assess whether it will (x) hold a subsequent special meeting of its shareholders at a later date with respect to the Share Issuance Proposal or (y) include the Share Issuance Proposal in its definitive proxy statement for the Company’s 2025 annual general meeting of shareholders. The Company also announced today that it has entered into an amendment to the SEPA, pursuant to which the Company and Yorkville agreed to amend certain of the provisions of the SEPA. Such amendment permits the Company to, at its sole discretion, temporarily suspend the use of its existing registration statement for its common shares under the SEPA (the “Registration Statement“). This suspension, known as a “Black Out Period,” may be implemented if the Company believes it is necessary to delay the disclosure of sensitive, material information or to update the Registration Statement or prospectus to ensure all information is accurate and not misleading. During any Black Out Period, Yorkville has agreed not to sell any of the Company’s common shares under the Registration Statement, although Yorkville may still sell these common shares through other legal exemptions, provided all relevant laws are followed. The Company has also committed that any Black Out Period imposed will not be more restrictive than those applied to its own directors and senior executives regarding the transfer of Company shares. Additionally, the Company will not issue any advance notices pursuant to the SEPA to Yorkville during a Black Out Period. If the Company publicly discloses the previously withheld material information during a Black Out Period, the suspension will end immediately, and Yorkville will be promptly notified. For further information on the SEPA, including important terms and conditions, please see the Company’s filings with the Securities and Exchange Commission, including the Company’s Current Reports on Form 8-K filed with the Securities and Exchange Commission from time to time. About InMed InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of products based on rare cannabinoids and their proprietary, small molecule drug analogs. For more information, visit www.inmedpharma.com. Investor Contact: Colin Clancy Vice President, Investor Relations and Corporate Communications T: +1.604.416.0999 E: ir@inmedpharma.com Cautionary Note Regarding Forward-Looking Information: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, the holding a subsequent special meeting of its shareholders at a later date with respect to the Share Issuance Proposal, the inclusion of the Share Issuance Proposal in its definitive proxy statement for the Company’s 2025 annual general meeting of shareholders, any suspension of the Company’s Registration Statement, the issuance of advance notices under the SEPA, the disclosure of withheld information and any notification the disclosure to Yorkville of the same. With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the ability to obtain all necessary regulatory approvals on a timely basis, or at all; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K, InMed’s Quarterly Report on Form 10-Q and other filings with the Security and Exchange Commission on www.sec.gov. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255571

Medical Cannabis Sleep Solution is Formulated with Minor Cannabinoids and Backed by Research At Bud & Mary’s, we’re deeply invested in understanding how cannabinoids interact with the brain and body, especially when it comes to improving individuals’ sleep quality.” — Lucas Nelson, Group President of Bud & Mary’s DES MOINES, IA, UNITED STATES, June 5, 2025 / EINPresswire.com / -- DES MOINES, Iowa (June 5, 2025) — Iowa medical cannabis patients can now access Bud & Mary’s NUO Sleep Tablets , a science-driven oral product that is the first of its kind in the state formulated with a blend of THC, CBD, and the minor cannabinoid CBN. Discreet, portable and precisely dosed, NUO Sleep Tablets are crafted to ease patients into a peaceful night and help them wake feeling refreshed. Scored for titrating doses, NUO Sleep Tablets serve medical cannabis patients seeking a smoke-free non-combustible, orally administered format that helps set the mood for sleep. The tablets -- free from sugar, preservatives, dyes, alcohols and artificial ingredients -- demonstrate Bud & Mary’s ongoing commitment to creating trusted, research -backed cannabis therapies. “At Bud & Mary’s, we’re deeply invested in understanding how cannabinoids interact with the brain and body, especially when it comes to improving individuals’ sleep quality” said Lucas Nelson, Group President of Bud & Mary’s. “NUO Sleep Tablets reflect that commitment, combining precise dosing with emerging research on minor cannabinoids such as CBN. It is the next step in our work to offer Iowa patients reliable, non-combustible therapies that are grounded in science and tailored for real-world needs.” Bud & Mary’s is one of the only U.S. cannabis license holders with a DEA Schedule 1 researcher license, enabling federally authorized cannabis research. With an ISO 17025-accredited analytical laboratory, cGMP/GACP-certified production, and multiple active clinical studies, the company sets a national standard for cannabis innovation, scientific rigor, and product safety. “Sleep is one of our most fundamental biological needs, yet so many people struggle to get consistent, uninterrupted sleep,” said Dr. Duncan Mackie, Director of Pharmacology & Experimental Therapeutics at Bud & Mary’s. “Research has shown that disturbed or insufficient sleep can affect mood, cognitive performance, and overall physical health. Now, NUO Sleep Tablets offer Iowa patients a reliable, science-backed option to assist them in obtaining a peaceful, uninterrupted night’s sleep.” As part of Bud & Mary’s dedication to researching how cannabis-based therapeutics can transform lives, the company is currently conducting a sleep-focused clinical trial with the University of Iowa, studying the effects of a patented cannabinoid-based therapeutic intradermal gel designed to improve sleep among individuals aged 50 or older with diagnosed sleep disturbances. Iowa medical cannabis patients with valid prescriptions can find NUO Sleep Tablets in licensed dispensaries across the state in 10-count and 30-count bottles. Patients can locate Iowa dispensaries that offer NUO Sleep Tablets in the store locator at this link. Product images are available at this link. Iowans seeking more information on obtaining a medical cannabis card can visit BudMary.com/IA/GetACard. For more information or to schedule an interview, please contact Irene Ancheta at 310-804-5493 or irene@themaverickpr.com. Bud & Mary’s: Crafted for You, Powered by Science. At Bud & Mary’s, we take a science-driven approach to crafting premium cannabis products designed for every individual. From our best-selling BATCH vape cartridges to our innovative water-soluble TheMyx powder and wellness-focused brands Become and NUO, every product is developed with care, precision, and an unwavering commitment to quality. Locally grown and rigorously tested, Bud & Mary’s products meet the highest standards of safety, consistency, and excellence. As we’ve pushed boundaries of cannabis innovation and expanded our offerings into Colorado, Michigan, Iowa, and Missouri, we’ve remained true to our family-owned and operated roots and people-focused values. For more information, visit BudMary.com. Continue the conversation on Facebook, Instagram, X, LinkedIn and TikTok. # # # Irene Ancheta Maverick Public Relations +1 310-804-5493 email us here Visit us on social media: LinkedIn Instagram Facebook TikTok X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.